CD274 and gastric cancer: Sintilimab combined with XELOX (oxaliplatin and capecitabine) significantly extends OS in patients with advanced gastric cancer: in the full study population, median OS increased by 2.9 months—to 15.2 months—and the PD-L1-positive population also achieved a 5.5-month improvement.